Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : to cut 300-400 product development jobs - Blick

07/01/2021 | 08:11am EDT
FILE PHOTO: A sign at a diagnostics site for Swiss pharmaceutical giant Roche

ZURICH (Reuters) - Roche plans to cut 300-400 jobs this year at product development (PD) sites, company executives including Chief Medical Officer Levi Garraway said during a recorded video call with employees obtained by Swiss newspaper Blick.

"We've made the difficult decision to reduce our workforce in PD by around 5-7% by the end of the year," Garraway said on the call. "And that equates to somewhere between 300 to 400 roles that will be impacted globally."

Roche employs 101,000 people worldwide.

The Basel-based company confirmed the video call took place and said in a statement it would be working with all employees to help soften the blow of losing their jobs.

"Based on current assumptions, the planned shifting of even more resources in Product Development (PD) into the development of new medicines may result in a reduction of 300-400 positions globally," a Roche spokesperson said in a statement to Reuters. "No further decisions have been taken at this point."

Roche has product development sites where employees' duties include clinical studies for prospective drugs that have emerged from research programmes in Switzerland, the United States, Britain, China and Canada, among other locations.

Jobs affected include business support positions, including project management, project delivery, learning and development, business management, coaching and administrative support, Roche managers said in the video call.

People due to lose their jobs will be told from August to October, with British employees first to be informed, followed by employees in other locations. Their work would cease in early November, a human resources manager said in the video.

"This is the hardest thing I've had to do since I've been in Roche," Felix Arellano, head of global drug safety, said on the recording.

Roche posted net profit of 15.1 billion Swiss francs ($16.3 billion) in 2020 as diagnostics for the pandemic bolstered falling drug sales.

($1 = 0.9254 Swiss francs)

(Reporting by John Miller; Editing by Mark Potter)

ę Reuters 2021
All news about ROCHE HOLDING AG
09:17aROCHE HOLDINGS AG : Credit Suisse gives a Neutral rating
08:58aROCHE : Canadian Blood Services selects Roche Diagnostics Canada as a partner of choice fo..
09/22ROCHE : Joins CG Oncology to Study Novel Immunotherapy Combination in Cancer Patients
09/22ROCHE : Rolls Out Three Respiratory Tests On Cobas 6800/8800 Systems
09/22PRESS RELEASE : Roche launches three respiratory -2-
09/22ROCHE : launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to..
09/22PRESS RELEASE : Roche launches three respiratory test panels on cobas 6800/8800 Systems in..
09/22Roche Launches Three Respiratory Test Panels on Cobas 6800/8800 Systems in CE Markets t..
09/21ROCHE : New Phase III Data Support the Benefit of Genentech's Tecentriq in Early-Stage Lun..
09/20ROCHE : Booster programme welcome but plans must be in place for boosters for all vaccinat..
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Sales 2021 61 371 M 66 382 M 66 382 M
Net income 2021 14 747 M 15 951 M 15 951 M
Net cash 2021 4 891 M 5 290 M 5 290 M
P/E ratio 2021 19,8x
Yield 2021 2,76%
Capitalization 298 B 322 B 322 B
EV / Sales 2021 4,77x
EV / Sales 2022 4,61x
Nbr of Employees 101 465
Free-Float 83,5%
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 340,05 CHF
Average target price 382,65 CHF
Spread / Average Target 12,5%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG10.05%322 644
JOHNSON & JOHNSON4.16%431 543
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ABBVIE INC.0.93%188 045